Heron Therapeutics (HRTX) Change in Accured Expenses (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Change in Accured Expenses data on file, last reported at -$2.9 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 150.41% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 72.84% YoY) and the FY2025 annual result came in at $10.6 million, up 10607.07% from the prior year.
• Change in Accured Expenses eased to -$2.9 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q3 2025 to a low of -$8.8 million in Q2 2025.
• A 5-year average of $547941.2 and a median of $346000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 993.31% in 2025, down 1465.12% in 2025.
• Tracing HRTX's Change in Accured Expenses over 5 years: stood at -$1.3 million in 2022, then surged by 594.04% to $6.4 million in 2023, then sank by 79.46% to $1.3 million in 2024, then soared by 170.63% to $3.5 million in 2025, then plunged by 181.17% to -$2.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.9 million (Q1 2026), $3.5 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.